Heron Therapeutics, Inc. is a commercial-stage biotechnology company dedicated to improving patient outcomes by developing and commercializing best-in-class treatments that address significant unmet medical needs. The company's mission is to advance the therapeutic standard of care through a portfolio of innovative therapies that combine proprietary science and technologies with well-established pharmacology. Heron focuses primarily on acute care and oncology care, aiming to enhance the quality of life for patients undergoing complex treatments.
Key Strategic Focus
Heron's strategic focus centers on developing and commercializing therapies that address critical needs in acute care and oncology. The company specializes in creating advanced drug delivery systems and formulations that improve the efficacy and safety profiles of existing pharmacological agents. Key technologies include the proprietary Biochronomer drug delivery platform, which enables sustained release of therapeutic agents over extended periods. Heron's primary markets encompass postoperative pain management and chemotherapy-induced nausea and vomiting (CINV), targeting conditions where current treatment options are inadequate.
Financials and Funding
As of the most recent financial reports, Heron Therapeutics reported annual revenue of approximately $144.3 million, reflecting a 13.6% increase compared to the previous year. The company's oncology care franchise generated $107.9 million in revenue in 2023, surpassing full-year guidance. Heron ended 2023 with cash and cash equivalents totaling $80.4 million. In May 2025, Heron announced a settlement with Mylan Pharmaceuticals to resolve ongoing patent litigations concerning CINVANTI and APONVIE injectable emulsions.
Pipeline Development
Heron's product pipeline includes several key candidates:
- ZYNRELEF: An extended-release solution combining bupivacaine and meloxicam for postoperative pain management. In January 2024, the FDA approved an expanded indication for ZYNRELEF, broadening its use to approximately 13 million procedures annually. The company plans to submit a Prior Approval Supplement for the ZYNRELEF Vial Access Needle in Q2 2024, with an anticipated launch in the second half of 2024.
- HTX-034: A non-opioid, fixed-dose combination product for postoperative pain management, currently in Phase 2 clinical trials.
- HTX-019: An intravenous formulation of aprepitant for the prevention of postoperative nausea and vomiting, approved as APONVIE.
Technological Platform and Innovation
Heron's proprietary Biochronomer technology is a polymer-based drug delivery platform designed to improve the therapeutic profile of injectable pharmaceuticals by enabling sustained release over extended periods. This platform underpins products like ZYNRELEF, providing prolonged pain relief and reducing the need for opioids. The company's innovative approach combines well-known pharmacological agents with advanced delivery systems to enhance efficacy and patient compliance.
Leadership Team
Heron's leadership team comprises experienced professionals with extensive backgrounds in the pharmaceutical and biotechnology industries:
- Craig Collard, Chief Executive Officer and Director
Mr. Collard has over two decades of experience in pharmaceutical leadership, previously serving as CEO of Veloxis Pharmaceuticals and Cornerstone Therapeutics. He holds a B.S. in Engineering from the Southern College of Technology.
- Ira Duarte, Executive Vice President and Chief Financial Officer
Ms. Duarte brings significant financial leadership experience, having served as CFO at Veloxis Pharmaceuticals. She is a Certified Public Accountant with a B.S. in Accounting from Florida Atlantic University.
- Dr. William Forbes, Executive Vice President and Chief Development Officer
Dr. Forbes has over 30 years of pharmaceutical product development experience, contributing to 14 marketing approvals. He holds a Doctor of Pharmacy degree from Creighton University.
- Mark Hensley, Chief Operating Officer
Mr. Hensley joined Heron in April 2025, bringing extensive operational leadership experience in the pharmaceutical industry.
- Brett Fleshman, Chief Business Officer
Mr. Fleshman joined Heron in August 2024, contributing 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices.
Leadership Changes
In April 2025, Heron appointed Mark Hensley as Chief Operating Officer, enhancing the company's operational leadership. In August 2024, Brett Fleshman joined as Chief Business Officer, bringing extensive experience in corporate and business development.
Competitor Profile
Market Insights and Dynamics
The global pain management market was valued at $71.8 billion in 2023, with a projected compound annual growth rate (CAGR) of 6.2% through 2028. The postoperative pain management segment alone accounted for $24.5 billion, growing at a 7.3% CAGR. The oncology pain management segment was valued at $18.3 billion, with a 5.9% CAGR.
Competitor Analysis
Heron operates in a competitive landscape with several key players:
- Pacira BioSciences: Specializes in non-opioid pain management solutions, with annual revenue of $541.3 million and R&D investment of $127.6 million.
- Cara Therapeutics: Focuses on developing and commercializing new chemical entities for pain management, reporting $63.2 million in revenue and $89.4 million in R&D investment.
- Jazz Pharmaceuticals: Offers a diverse portfolio, including pain management products, with annual revenue of $3.2 billion and R&D investment of $456.7 million.
These competitors invest heavily in R&D and have established market presences, intensifying the competitive landscape for Heron.
Strategic Collaborations and Partnerships
In January 2024, Heron announced a partnership with CrossLink Life Sciences, LLC to expand promotional efforts for ZYNRELEF. This collaboration aims to provide up to 650 additional sales representatives promoting ZYNRELEF to orthopedic surgeons, enhancing market penetration and adoption.
Operational Insights
Heron's strategic considerations include:
- Market Position: Leveraging proprietary technologies to differentiate products in the competitive pain management and oncology care markets.
- Competitive Advantages: Utilizing the Biochronomer drug delivery platform to offer sustained-release formulations that improve patient outcomes and reduce opioid dependence.
- Regulatory Navigation: Successfully obtaining FDA approvals and expanding product indications to increase market reach.
Strategic Opportunities and Future Directions
Heron's strategic roadmap includes:
- Product Expansion: Advancing the development and commercialization of pipeline candidates like HTX-034 and HTX-019 to address unmet needs in postoperative pain and nausea management.
- Market Penetration: Enhancing sales and marketing efforts through strategic partnerships to increase adoption of existing products.
- Innovation: Continuing to invest in R&D to develop novel therapies that leverage proprietary drug delivery technologies, maintaining a competitive edge in the biotechnology industry.
Contact Information
- Website: www.herontx.com
- LinkedIn: Heron Therapeutics LinkedIn
- Twitter: Heron Therapeutics Twitter
